癌症中的PI3K：异构体的不同作用、激活模式及治疗靶点
PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting.
作者信息
Thorpe Lauren M, Yuzugullu Haluk, Zhao Jean J
机构信息
1] Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA. [2] Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts 02115, USA. [3] Program in Virology, Harvard Medical School, Boston, Massachusetts 02115, USA.
1] Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA. [2] Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts 02115, USA.
出版信息
Nat Rev Cancer. 2015 Jan;15(1):7-24. doi: 10.1038/nrc3860.
Abstract
Phosphatidylinositol 3-kinases (PI3Ks) are crucial coordinators of intracellular signalling in response to extracellular stimuli. Hyperactivation of PI3K signalling cascades is one of the most common events in human cancers. In this Review, we discuss recent advances in our knowledge of the roles of specific PI3K isoforms in normal and oncogenic signalling, the different ways in which PI3K can be upregulated, and the current state and future potential of targeting this pathway in the clinic.
摘要
磷脂酰肌醇3-激酶（PI3Ks）是响应细胞外刺激的细胞内信号传导的关键协调者。PI3K信号级联的过度激活是人类癌症中最常见的事件之一。在本综述中，我们讨论了关于特定PI3K亚型在正常和致癌信号传导中的作用、PI3K上调的不同方式以及该通路在临床上的靶向治疗现状和未来潜力的最新研究进展。
相似文献
1
PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting.癌症中的PI3K：异构体的不同作用、激活模式及治疗靶点
Nat Rev Cancer. 2015 Jan;15(1):7-24. doi: 10.1038/nrc3860.
2
The relation between PI3K/AKT signalling pathway and cancer.PI3K/AKT 信号通路与癌症的关系。
Gene. 2019 May 25;698:120-128. doi: 10.1016/j.gene.2019.02.076. Epub 2019 Mar 5.
3
Structure, function and inhibition of the phosphoinositide 3-kinase p110α enzyme.磷酸肌醇 3-激酶 p110α 酶的结构、功能和抑制。
Biochem Soc Trans. 2014 Feb;42(1):120-4. doi: 10.1042/BST20130255.
4
Comparing the roles of the p110α and p110β isoforms of PI3K in signaling and cancer.比较 PI3K 的 p110α 和 p110β 同工型在信号转导和癌症中的作用。
Curr Top Microbiol Immunol. 2010;347:55-77. doi: 10.1007/82_2010_63.
5
PI3K isoform-selective inhibitors: next-generation targeted cancer therapies.PI3K亚型选择性抑制剂：新一代靶向癌症疗法
Acta Pharmacol Sin. 2015 Oct;36(10):1170-6. doi: 10.1038/aps.2015.71. Epub 2015 Sep 14.
6
Phosphatidylinositol 4-kinases, phosphatidylinositol 4-phosphate and cancer.磷脂酰肌醇 4-激酶、磷脂酰肌醇 4-磷酸与癌症。
Cancer Lett. 2012 Dec 28;325(2):125-31. doi: 10.1016/j.canlet.2012.06.009. Epub 2012 Jun 28.
7
Advances in subunits of PI3K class I in cancer.I类磷脂酰肌醇-3激酶亚基在癌症中的研究进展。
Pathology. 2014 Apr;46(3):169-76. doi: 10.1097/PAT.0000000000000066.
8
PI3K/Akt signalling pathway and cancer.PI3K/Akt信号通路与癌症
Cancer Treat Rev. 2004 Apr;30(2):193-204. doi: 10.1016/j.ctrv.2003.07.007.
9
Targeting PI3K signaling in cancer: Challenges and advances.靶向癌症中的 PI3K 信号通路：挑战与进展。
Biochim Biophys Acta Rev Cancer. 2019 Apr;1871(2):361-366. doi: 10.1016/j.bbcan.2019.03.003. Epub 2019 Apr 1.
10
PI3K inhibitors for cancer therapy: what has been achieved so far?用于癌症治疗的PI3K抑制剂：目前已取得哪些成果？
Curr Med Chem. 2009;16(8):916-30. doi: 10.2174/092986709787581905.
引用本文的文献
1
Living on the Edge: ROS Homeostasis in Cancer Cells and Its Potential as a Therapeutic Target.边缘生存：癌细胞中的活性氧稳态及其作为治疗靶点的潜力
Antioxidants (Basel). 2025 Aug 16;14(8):1002. doi: 10.3390/antiox14081002.
2
Regulatory roles of circular RNAs in Wnt and other oncogenic signaling pathways in breast cancer progression: a comprehensive review.环状RNA在乳腺癌进展中Wnt及其他致癌信号通路中的调控作用：综述
Eur J Med Res. 2025 Aug 14;30(1):750. doi: 10.1186/s40001-025-02967-9.
3
Green Synthesis of Gold Nanoparticles and Their Cytotoxic Effect in Breast Cancer: An Experimental and Theoretical Study.金纳米粒子的绿色合成及其对乳腺癌的细胞毒性作用：一项实验与理论研究。
ACS Appl Bio Mater. 2025 Aug 18;8(8):7490-7503. doi: 10.1021/acsabm.5c01172. Epub 2025 Jul 31.
4
PI3K/AKT/mTOR Axis in Cancer: From Pathogenesis to Treatment.癌症中的PI3K/AKT/mTOR轴：从发病机制到治疗
MedComm (2020). 2025 Jul 30;6(8):e70295. doi: 10.1002/mco2.70295. eCollection 2025 Aug.
5
The tumor microbiome in cancer progression: mechanisms and therapeutic potential.癌症进展中的肿瘤微生物群：机制与治疗潜力
Mol Cancer. 2025 Jul 15;24(1):195. doi: 10.1186/s12943-025-02403-w.
6
Research progress on the anti-cancer mechanisms of edible salty-flavored Chinese materia medica.食用咸味中药抗癌机制的研究进展
Front Pharmacol. 2025 Jun 20;16:1598978. doi: 10.3389/fphar.2025.1598978. eCollection 2025.
7
PI3Kβ moonlights as a protein kinase: driving fatty acid metabolism and histone acetylation in cancer.PI3Kβ兼具蛋白激酶功能：驱动癌症中的脂肪酸代谢和组蛋白乙酰化。
Cancer Biol Med. 2025 Jun 27;22(6):539-42. doi: 10.20892/j.issn.2095-3941.2025.0216.
8
The Precision-Guided Use of PI3K Pathway Inhibitors for the Treatment of Solid Malignancies.PI3K 通路抑制剂在实体恶性肿瘤治疗中的精准应用
Biomedicines. 2025 May 28;13(6):1319. doi: 10.3390/biomedicines13061319.
9
Adaptation to Arginine Deprivation Leads to a More Aggressive, Therapy-Resistant Phenotype in HNSCC Cells.对精氨酸剥夺的适应导致头颈部鳞状细胞癌（HNSCC）细胞出现更具侵袭性、抗治疗的表型。
Biomolecules. 2025 Jun 19;15(6):900. doi: 10.3390/biom15060900.
10
Innate immunity and the NF-κB pathway control prostate stem cell plasticity, reprogramming and tumor initiation.固有免疫和核因子κB信号通路控制前列腺干细胞可塑性、重编程及肿瘤起始。
Nat Cancer. 2025 Jun 23. doi: 10.1038/s43018-025-00994-3.
本文引用的文献
1
CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors.CDK4/6 抑制剂使 PIK3CA 突变型乳腺癌对 PI3K 抑制剂敏感。
Cancer Cell. 2014 Jul 14;26(1):136-49. doi: 10.1016/j.ccr.2014.05.020. Epub 2014 Jul 4.
2
Inactivation of PI(3)K p110δ breaks regulatory T-cell-mediated immune tolerance to cancer.PI(3)K p110δ 的失活破坏了调节性 T 细胞介导的对癌症的免疫耐受。
Nature. 2014 Jun 19;510(7505):407-411. doi: 10.1038/nature13444. Epub 2014 Jun 11.
3
Vulnerabilities of PTEN-TP53-deficient prostate cancers to compound PARP-PI3K inhibition.PTEN-TP53 缺陷型前列腺癌对复合 PARP-PI3K 抑制的易感性。
Cancer Discov. 2014 Aug;4(8):896-904. doi: 10.1158/2159-8290.CD-13-0230. Epub 2014 May 27.
4
PI3K isoform dependence of PTEN-deficient tumors can be altered by the genetic context.PTEN 缺陷型肿瘤的 PI3K 同工型依赖性可被遗传背景改变。
Proc Natl Acad Sci U S A. 2014 Apr 29;111(17):6395-400. doi: 10.1073/pnas.1323004111. Epub 2014 Apr 15.
5
PI3K class II α controls spatially restricted endosomal PtdIns3P and Rab11 activation to promote primary cilium function.PI3K 类 IIα 控制空间受限的内体 PtdIns3P 和 Rab11 的激活，以促进初级纤毛功能。
Dev Cell. 2014 Mar 31;28(6):647-58. doi: 10.1016/j.devcel.2014.01.022.
6
Antagonism of EGFR and HER3 enhances the response to inhibitors of the PI3K-Akt pathway in triple-negative breast cancer.表皮生长因子受体（EGFR）和人表皮生长因子受体 3（HER3）的拮抗作用增强了三阴性乳腺癌对 PI3K-Akt 通路抑制剂的反应。
Sci Signal. 2014 Mar 25;7(318):ra29. doi: 10.1126/scisignal.2005125.
7
PI3Kδ inhibition hits a sensitive spot in B cell malignancies.PI3Kδ 抑制在 B 细胞恶性肿瘤中击中敏感点。
Cancer Cell. 2014 Mar 17;25(3):269-71. doi: 10.1016/j.ccr.2014.02.012.
8
Idelalisib--a PI3Kδ inhibitor for B-cell cancers.idelalisib——一种用于治疗B细胞癌症的PI3Kδ抑制剂。
N Engl J Med. 2014 Mar 13;370(11):1061-2. doi: 10.1056/NEJMe1400055.
9
Hematopoiesis and RAS-driven myeloid leukemia differentially require PI3K isoform p110α.造血作用和 RAS 驱动的髓性白血病对 PI3K 同工型 p110α 的需求不同。
J Clin Invest. 2014 Apr;124(4):1794-809. doi: 10.1172/JCI69927. Epub 2014 Feb 24.
10
Alterations of INPP4B, PIK3CA and pAkt of the PI3K pathway are associated with squamous cell carcinoma of the lung.PI3K信号通路中INPP4B、PIK3CA和磷酸化Akt的改变与肺鳞状细胞癌相关。
Cancer Med. 2014 Apr;3(2):337-48. doi: 10.1002/cam4.191. Epub 2014 Feb 5.
Zotero 插件